Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine a safe and tolerable dose of LIP-01
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| One gram LIP-01 per day | Experimental | One gram LIP-01 per day for 12 weeks |
|
| Two grams LIP-01 per day | Experimental | Two grams LIP-01 per day for 12 weeks |
|
| 0.333 grams LIP-01 per day | Experimental | 0.333 grams LIP-01 per day for 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LIP-01 | Dietary Supplement | comparison of different dosages of natural health product |
|
| Measure | Description | Time Frame |
|---|---|---|
| To determine a safe and tolerable dose of LIP-01 | 12 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard Lewanczuk, MD, PhD, FRCPC | University of Alberta | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medicus Research, LLC | Northridge | California | 91325 | United States | ||
| The Northern Alberta Clinical Trials and Research Centre |
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Edmonton |
| Alberta |
| T6G 2C8 |
| Canada |
| D009750 |
| Nutritional and Metabolic Diseases |